Literature DB >> 17312001

Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML.

Martin Bornhäuser, Thomas Illmer, Markus Schaich, Silke Soucek, Gerhard Ehninger, Christian Thiede.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17312001     DOI： 10.1182/blood-2006-09-047225

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  56 in total

Review 1.  Molecular therapy for acute myeloid leukaemia.

Authors:  Catherine C Coombs; Martin S Tallman; Ross L Levine
Journal:  Nat Rev Clin Oncol       Date:  2015-12-01       Impact factor: 66.675

Review 2.  FLT3 inhibitors in AML: are we there yet?

Authors:  Akshay Sudhindra; Catherine Choy Smith
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

3.  Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of a Matched Identical Sibling: A Meta-Analysis.

Authors:  Zhichao Li; Yinmei Liu; Qing Wang; Linjun Chen; Liyuan Ma; Siguo Hao
Journal:  Acta Haematol       Date:  2019-02-26       Impact factor: 2.195

4.  Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.

Authors:  Betül Oran; Jorge Cortes; Amer Beitinjaneh; Hsiang-Chun Chen; Marcos de Lima; Keyur Patel; Farhad Ravandi; Xuemei Wang; Mark Brandt; Borje S Andersson; Stefan Ciurea; Fabio P Santos; Leandro de Padua Silva; Elizabeth J Shpall; Richard E Champlin; Hagop Kantarjian; Gautam Borthakur
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-04       Impact factor: 5.742

5.  Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia.

Authors:  Mike Fischer; Ulf Schnetzke; Bärbel Spies-Weisshart; Mario Walther; Maximilian Fleischmann; Inken Hilgendorf; Andreas Hochhaus; Sebastian Scholl
Journal:  Haematologica       Date:  2016-12-29       Impact factor: 9.941

Review 6.  The Future of Targeting FLT3 Activation in AML.

Authors:  Mark B Leick; Mark J Levis
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

7.  Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation.

Authors:  Takeshi Kondo; Atsushi Yasumoto; Kotaro Arita; Jun-Ichi Sugita; Akio Shigematsu; Kohei Okada; Mutsumi Takahata; Masahiro Onozawa; Kaoru Kahata; Yukari Takeda; Masato Obara; Satoshi Yamamoto; Tomoyuki Endo; Mitsufumi Nishio; Norihiro Sato; Junji Tanaka; Satoshi Hashino; Takao Koike; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2010-01-20       Impact factor: 2.490

Review 8.  FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.

Authors:  Michael R Grunwald; Mark J Levis
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

9.  High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia.

Authors:  Hyoung Jin Kang; Ji Won Lee; Sang Hyeok Kho; Min Jeong Kim; Young Jin Seo; Hyery Kim; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

10.  Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification.

Authors:  Axel Rolf Zander; Ulrike Bacher; Jürgen Finke
Journal:  Dtsch Arztebl Int       Date:  2008-09-26       Impact factor: 5.594
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.